Key result
HIV infection is estimated to cause symptomatic heart failure in 8% to 10% of patients over a 2- to 5-year period, while HAART may increase the risk of peripheral and coronary arterial diseases.
While HAART improves overall survival in HIV patients, it introduces new cardiovascular risks including coronary and peripheral arterial diseases, compounding the baseline risk of HIV-related heart failure.
No takes yet. Share an insight, caveat, or question.
Anticipates large HIV-related heart failure burden; leaves open prospective validation and management strategies in the modern ART era.
Giuseppe Bárbaro (2002) conducted a review in HIV infection. HAART was evaluated. HIV infection is estimated to cause symptomatic heart failure in 8% to 10% of patients over a 2- to 5-year period, while HAART may increase the risk of peripheral and coronary arterial diseases.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: